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ABSTRACT: 
 
This paper describes a decision-support tool that integrates Monte Carlo simulation 
data derived using a stochastic discrete-event simulation model to mimic process 
fluctuations with advanced multivariate statistical techniques to help pinpoint the 
potential root causes of sub-optimal short term facility fit issues. Principal component 
analysis combined with clustering algorithms was used to analyse the complex 
datasets from complete industrial batch processes for biopharmaceuticals. The 
challenge of visualising the multidimensional nature of the dataset was addressed 
using hierarchical and K-means clustering as well as parallel co-ordinate plots to help 
identify process fingerprints and characteristics of clusters leading to sub-optimal 
facility fit issues. Industrially-relevant case studies are presented that focus on 
technology transfer challenges for therapeutic antibodies moving from early phase to 
late phase clinical trials. The case study details how sub-optimal facility fit can be 
alleviated by allocating alternative product pool tanks. The impact of this operational 
change is then assessed by reviewing an updated process fingerprint. 
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1. Introduction 
Long term facility fit issues are generally concerned with the future proofing of 
manufacturing facilities and platform processes (Stonier et al.,  2009, 2012). Any 
challenges highlighted can be addressed over time with the development of new 
technologies and large capital projects. Short term facility fit issues are those that 
arise due to the batch-to-batch variability associated with a single process and there 
may be insufficient time to make significant changes to facilities so early 
identification of issues is crucial. 
Tech transfer of pilot scale processes into facilities during late phase clinical 
trials of a drug candidate can often lead to short term facility fit issues (e.g. Kelley, 
2009; Chang, 2011) . The impact of process fluctuations becomes more pronounced 
during tech transfer since mismatches in equipment sizes are not easy to adapt to at 
large scale. Predicting and understanding the root causes of sub-optimal facility fit 
becomes critical so as to minimise the probability of having to discard expensive 
product and remove barriers to robust, scalable process design. The ideal is for a 
process in development to complete technology transfer to full scale manufacturing 
with no redevelopment costs or surprises. Essential to achieving this is a systematic 
method for analysing large complex datasets and extracting critical combinations of 
fluctuations that lead to product loss and scheduling delays. This paper explores how 
best to integrate large datasets, derived from stochastic simulations of tech transfer 
batch fluctuations, with advanced multivariate analysis and visualisation techniques 
such as clustering, principal component analysis (PCA), and parallel co-ordinate plots 
so as to help identify the potential root causes of sub-optimal short term facility fit 
issues. 
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Multivariate analysis techniques such as PCA have been used in a range of 
biotechnology applications such as analysing vaccine production runs to identify 
rejected batches and sources of variation (Thomassen et al, 2010), understanding the 
impact of raw material variability on cell culture performance (Lee et al, 2012; Kirdar 
et al, 2010), analysing the impact of chromatography operating conditions on 
chromatogram profiles (Pate et al,, 1999, 2004; Malmquist and Danielsson, 1994; 
Larson et al., 2003; Edwards-Parton et al., 2008; Hou et al., 2011), and assessing 
process comparability for cell culture operations across different scales of production 
(Kirdar et al, 2007). 
Most works on MVA utilise historical datasets. However, the nature of tech 
transfer activities where a single batch is usually run to identify facility fit issues and 
fix them before further batches are operated means that such datasets do not exist for 
this problem. However, companies with experience in tech transfer activities can 
identify typical process fluctuations seen from the expected base case performance. 
However, their combined impact is not known nor their contribution to product loss. 
Hence in this work Monte Carlo simulations were used to generate the range and 
likelihood of possible outcomes in terms of process variation and the consequences on 
key metrics such as product mass loss and cost of goods (COG).  
This paper builds on the flexible database-driven simulation platform 
described in Stonier et al, (2009, 2012) that captures the mass balances, equipment 
sizing, dynamic resource allocation and process economics of purification sequences 
in monoclonal antibody manufacturing processes. Previous work by the authors 
(Stonier et al., 2009, 2012) discusses the use of the tool to perform a small number of 
simulation runs to generate sufficient data to assess the impact of a single parameter 
change. This paper describes the extension of the tool to mimic the stochastic nature 
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of industrial batch processes when transferred to large-scale facilities and to identify 
the potential root causes of short term facility fit issues. This was achieved by 
building in capabilities to run Monte Carlo simulations and exploring how best to 
integrate stochastic results with advanced multivariate statistical analysis techniques. 
Monte Carlo simulations result in very large datasets and hence visualising the 
results of the MVA becomes more challenging. Although PCA might reduce 
hundreds of datasets to a few principal components, it does not automatically identify 
clusters of batches with similar characteristics for further examination. Hence in this 
paper, algorithms adapted from Thornhill et al (2006) are used to achieve hierarchical 
and k-means clustering of the datasets so as to identify significant clusters of batches. 
Multidimensional visualization of each cluster’s characteristics in terms of the raw 
data (e.g. cell culture titre) is achieved through the generation of novel multiple 
‘stacked’ parallel co-ordinate plots; this is in constrast to other works (eg Wang et al., 
2004) where parallel co-ordinate plots are used to plot PC scores rather than reverting 
to the actual process data. The resulting facility fingerprints enhance process 
understanding of interactions between variables in an informative and clear manner. 
 
2. Problem Domain 
Upon technology transfer of a process from pilot scale to large scale, a GMP 
engineering batch is normally carried out to test performance and identify facility fit 
issues. Until this point, data is only available from the laboratory and pilot scales of 
the process. The first batch at large scale is subject to a much greater degree of 
uncertainty that would normally be expected between subsequent batches. This 
uncertainty is due in part to scale effects such as variability introduced by operating 
larger chromatography columns or increased product holdup in systems. The impact 
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of this variability becomes more exaggerated at large scale where any equipment 
limitations are difficult to adapt to. As a result, the first batch at large scale is more 
difficult to predict than any other batch. Four key parameters were identified as key to 
the variability at scale: product titre, step yields, chromatography eluate volumes and 
filter flux rates. Representative triangular distributions were derived through 
discussion with industrial experts (Table 1). These four sources of variability are 
discussed further below. 
 
2.1. Product Titre 
This variation in the total amount product entering into the purification process is felt 
across all chromatography steps since the number of cycles is determined by the mass 
load of product, making it an important parameter to capture. Some variation in 
average product titres upon scale up is expected due to the inherent uncertainty 
associated with biological systems and whilst not fully understood, contributing 
factors include: changes in vessel geometry and subsequent hydrodynamic affects, the 
differing levels of control of critical factors such as pH, temperature and gas mixtures 
within different reactors. The impact of these factors is complex and results in varying 
levels of uncertainty for different products and cell lines. The value of ±10% was 
determined through discussions with industrial advisors and represents a reasonable 
level of variation for a well-understood process from pilot scale to large scale 
manufacturing. The degree with which titres may vary however can be difficult to 
predict and a wider range may need to be considered for some products, especially 
where the differences in scale upon tech transfer are large.  
   
2.2. Step Yields 
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Variation in yield losses across steps are typically small as represented by the 
relatively narrow ranges specified in Table 1. The case studies in this paper are 
concerned with a hypothetical first batch at scale where fine tuning with respect to 
minimising yield losses such as optimising flush volumes to minimise losses through 
holdup may not have been fully identified. Hence this variation may be reduced 
further over subsequent batches. A larger range specified for chromatography 
operations is related to issues surrounding eluate volumes as discussed below.  
 
2.3. Chromatography Eluate Volumes 
Variability in the eluate volumes from the chromatography operations was 
highlighted as one of the largest factors impacting facility fit at scale. When using 
collection criteria based on UV traces, a small variation in the position of the peak can 
have a large effect on the volume collected particularly for steps where significant 
leading or tailing on elution peaks may occur. Certain chromatography steps for 
example may be highly sensitive to the pH and conductivity of the elution buffer. 
When considering a process at scale which may use inline dilution for buffers, the 
control over pH and conductivity is generally less precise than can be achieved at the 
laboratory scale. The result may be different binding profiles. Different batches of 
buffers can also influence the binding and elution profiles. Furthermore, when tech 
transfer activities are planned prior to the process limits evaluation validation studies 
during Phase III clinical trials, most of the manufacturing data would be from lab-
scale or small-scale experiments with little indication of the potential variability in 
elution performance. As a result, a value of ±50% in eluate volumes was considered 
to reflect this uncertainty as a worst case scenario for most processes.  
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2.4. Filter Flux Rates 
Filter flux rate variability can impact on the process schedule. The different pressure 
and flow rate capabilities of equipment at different scales can lead to uncertainty in 
the achievable flux rates. These are typically in the ±10% range. 
 
3. Method 
A database-driven discrete-event simulation tool (Stonier et al. 2009 and submitted) 
for modelling the logistics and process economics of antibody process was used as the 
core evaluation engine for this study. It was adapted to perform Monte Carlo 
simulations and handle the larger datasets required so as to mimic the impact of 
process fluctuations on the key outputs. A series of multivariate and visualisation 
analyses were then explored to examine the stochastic simulation outputs. These are 
elaborated upon further in the following sections. 
 
3.1. Tool Overview 
A database-driven discrete-event simulation tool was built to model the logistics and 
economics of alternative purification strategies. The overall structure along with the 
key input and output parameters is shown in Stonier et al. (2012). The benefits of a 
database-driven approach using MySQL (MySQL AB, Uppsala, Sweden) were 
harnessed to capture the process, business and risk features of multiple 
biopharmaceutical purification sequences in a multiproduct facility and better manage 
the large datasets required for multiple processes, uncertainty analysis and 
optimisation. The dynamic features of bioprocesses and impact of resource 
constraints, including suite availability, were captured through linkage to a discrete-
event simulation engine, Extend (Imagine That! Inc, San Jose, USA) that ran in the 
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background requiring no end-user interaction. This was achieved by adopting a 
router-based approach to automatically adapt to a number of process and facility 
configurations that may be specified by the user in the database without the need for 
recoding. Universal modelling language (UML) was used to provide a conceptual 
representation of the hierarchical breakdown of key activities and facility resources 
used in purification campaigns along with the relationships between them. The UML 
hierarchical structure was mapped to the database where it was used to define the data 
tables and relationships and to the simulation engine where it defined the key 
procedures to be implemented.  
 
3.2. Database Configuration for the Monte Carlo Simulations 
The simulation database was modified to handle the more complex datasets from 
stochastic simulations. In this paper only triangular distributions were used, but the 
new data structure was designed to allow different distribution functions to be defined 
in the future. The distributions were defined with two fields in the database tables. 
The fields were defined in addition to the existing data so as to allow the simulation to 
be operated in deterministic mode without modification. The first field was a 
numerical identifier which relates to the shape of the distribution. The second field 
was a coded variable containing the parameters for the bounds of the distribution. The 
value in the identifier field determined which function would be used by the 
simulation and the coded variable stored the inputs to the function as a set of comma 
separated variables. This approach to capturing stochastic inputs enabled 
modifications to be made that had limited effect on the existing data structure whilst 
allowing for the maximum degree of flexibility.  
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As well as defining a data structure for the input parameters, the results from 
multiple iterations were stored in such a way so as to allow the key inputs and outputs 
of each iteration to be isolated for more in-depth analysis on the root causes of the 
output observed. 
 
3.3 Stochastic Discrete-Event Simulation Engine 
The discrete-event simulation engine described in Stonier et al. (2009, 2012) was 
configured to run Monte Carlo simulations by tying a random number generator into 
new functions which could generate the values within the distributions described in 
the database. The numerical identifier field was used to determine if a distribution 
should be used. A value of 1 directs the simulation engine to use the original 
deterministic (point) value. Values other than 1 correspond to different shapes of 
distribution (e.g. a triangular distribution).  
 
3.4. Principal Component Analysis Method 
Methods for principal component analysis have been widely documented. The method 
used in this paper was derived from Thornhill et al. (2006) and uses singular value 
decomposition. The output data from the simulations were first transformed by mean 
centring and stored as a comma separated variable file which was then imported. The 
PCA analysis was carried out using SPSS Statistics (IBM Corp., NY).  
The main aim of principal component analysis is to reduce the dimensionality 
of a dataset whilst minimising the loss of information. The primary output of the 
analysis is a new data set where the original variables have been replaced by principal 
components and the values for each variable are transformed into scores within each 
principal component. The weighting of the original variables within the principal 
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components will determine how the scores relate back to the original data. However, 
it can be said that the structure of the scores will represent the structure of the original 
dataset and if successful the structure will be evident in a lower dimension than the 
original data and thus easier to visualise.  
Eigenvalues are used to determine which principal components are of key 
importance. Several methods are used to test for significance. The most common of 
these is to divide each eigenvalue by the mean of all eigenvalues and consider all 
principal components with an eigenvalue greater than 1 as significant. The 
eigenvalues can also be plotted for each principal component, the result is a scree plot 
as shown in Figure 5. Visual analysis of the scree plot may determine that the average 
eigenvalue method is not suitable if the data is not highly correlated. Instead a visual 
analysis of the scree is required to identify significant changes in gradient. The ideal 
scree plot will consist of a small number of high value eigenvalues followed by a 
sudden drop and a gradual tailing of the remaining eigenvalues. The principal 
components before the drop are considered significant and those after have less 
statistical value.  
Upon identification of the key principal components the scores from each 
component can be analysed using cluster analysis. SPSS was used to assess the 
performance of two clustering methods. These were hierarchical clustering, and K-
means clustering. Hierarchical clustering was used by Thornhill et al. (2006) with a 
data set of similar complexity and structure and whilst various methods were used to 
improve the method, hierarchical clustering was not able to satisfactorily elucidate the 
clusters within the dataset generated in this analysis. An example dendrogram is 
shown in Appendix A. Instead K-means clustering was used. The K-means clustering 
algorithm used in this paper was a function within SPSS. 
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SPSS was also used to generate graphical outputs in the form of scatter plot 
matrices and parallel co-ordinate plots. Both methods were used to visualise the 
higher dimensional datasets generated as part of this analysis and are discussed in 
more detail throughout this paper.   
 
3.5. Setup 
The case study looks at the first batch at scale. The process description for a 
hypothetical 10,000L facility is summarised in Fig 1 and Table 2. The aim was to 
identify potential short term facility fit issues upon tech transfer and the probability 
that they would be realised. In addition to facility fit issues, the case study also 
highlights how the sensitivity of a process to uncertainty can change with respect to 
facility design. The simulation engine was configured to run Monte Carlo simulations. 
The results were first analysed to investigate potential facility fit issues. Modifications 
were then made to the simulated process to improve facility fit and the Monte Carlo 
simulations were repeated with the improved process. The complexity of each dataset 
was then reduced using principle component analysis combined with clustering to 
reduce the dimensionality and eliminate noise (Thornhill et al. 2006). The results 
were compared to assess the impact of the process change.  
The appropriate number of principal components was selected by a visual 
analysis of the eigenvalues plotted for each principal component. After selection of 
the principal components, clusters in the dataset were identified using K-means 
clustering. The clusters were generated by analysing the component scores. Finally, 
the input parameter distributions for each cluster was visualised on vertical parallel 
co-ordinate plots. The Monte Carlo simulation was run for 1000 iterations to generate 
the following results.  
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4. Results 
4.1 Identifying Sub-optimal Facility Fit 
4.1.1 Mass Throughput Profile 
One of the key parameters of interest is the mass throughput of the facility (kg/batch). 
In many cases the planning of manufacturing campaigns will be determined well in 
advance of the first batches at scale, therefore it is important to have an accurate 
prediction of facility throughput early on in the development lifecycle. The stochastic 
tool was used to predict the likelihood of product loss upon tech transfer using Monte 
Carlo simulation, given the expected fluctuations in key performance indicators and 
purification operating parameters indicated in Table 1.Figure 2 shows the predicted 
facility throughput for the processes running in the 10,000L facility. Based on 
deterministic values, the predicted facility throughput would be calculated at 
11Kg/batch. The values predicted by the simulation fall well short of this value. A 
very small proportion of batches meet the expected throughput. This is suggestive of 
facility fit issues and prompted further investigation.  
 
4.1.2. Risk Hotspots for Facility Fit 
The Monte Carlo simulation data for the pool volumes after each step in the 
purification process was examined to identify the location of the equipment 
limitations causing the facility fit issues. The simulation engine maintained a log of 
events that occurred during each simulation run. A section of this log was dedicated to 
vessel operations and an error event was recorded when the amount of material 
exceeded a tank’s maximum volume. Review of the log showed that an over-fill event 
occurred in two of the product pool tanks in a number of runs. Since step yields and 
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eluate volumes are stochastic variables some variability of pool volumes was 
expected. Figure 3 shows the distribution of the pool volumes at each step. With the 
exception of the harvest pool which in this simulation is defined as a fixed value 
entering the process, variation in the pool volumes is evident. Figure 3(a) identifies 
the virus inactivation and anion exchange chromatography pool volumes as risk 
hotspots.  
The vertical histogram plotted alongside each column of data points shows a 
spike in the distributions at 2500L for both of these tanks. This is due to the fact that 
the largest volume that can be stored in these tanks was 2500L. Surplus volume was 
diverted to waste and the product was lost impacting throughput on a large number of 
batches. This is a facility fit issue which must be addressed. In this case a facility 
modification was possible to re-route the product into alternative larger tanks. The 
effect of this modification is shown in Figure 3(b) 
With the tank volumes increased to handle the predicted pools, the volume of 
the spike in the distribution was removed. The result of this modification would be to 
increase the volume entering into subsequent steps and could also move the 
bottleneck downstream. In this instance however sufficient capacity was installed and 
no additional tank issues were apparent. The impact of this facility fix on the facility 
throughput can be seen in Figure 2 (dotted line), with the throughput closer to the 
predicted value of 11kg/batch. 
4.1.3. Probability of Meeting Demand 
The data shown in Figure 4 can be used to generate probabilities of being able to 
manufacture sufficient material within a number of batches and hence better manage 
manufacturing risk. Figure 4 shows the probability of being able to meet varying 
demands within three batches. This illustrates that the minimum guaranteed demand 
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for the modified facility is almost double that of the base case facility. This is because 
not only is the throughput of the modified facility higher, it is less variable.  
 
4.2 Principal Component Analysis 
In order to gain more insight into the performance of the process in the 10,000L 
facility principal component analysis was used to reduce the complexity of the 
dataset. The two datasets from the base case and modified facility were analysed 
individually using the same procedure. Firstly the number of significant principal 
components was identified by plotting their eigenvalues as shown in Figure 5. 
 
4.2.1 Principal Component Selection 
The average eigenvalue method, which defines significant components as having 
eigenvalues greater than 1 is not suitable for these datasets as this would include a 
number of principal components which add little value. Instead the appropriate 
number of principal components was selected by a visual analysis of the dataset. In 
this case for the base case the first 5 principal components were selected and for the 
modified facility the first 6. In both cases selection of any additional components 
added little to the integrity of the dataset. 
4.2.2 Cluster Identification 
After selection of the principal components, hierarchical clustering was used to 
determine the number of significant clusters by visual inspection of the resulting 
dendrogram (Appendix 1) which clearly shows three parent clusters dividing into six 
distinct clusters (at an average distance between clusters of 20 units). Further 
branching leads to less distinct clusters. The method of k-means clustering was then 
used to identify the membership of six distinct clusters. To aid visualisation, the key 
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principal components were plotted against each other on a scatter plot matrix (Figure 
5). Each of the cells in the scatter plot matrices shown in Figure 5 were generated by 
plotting the component scores from each principal component against each other. For 
example, all the charts in the first row show principal component 1 scores plotted 
against: themselves in column 1, principal component 2 scores in column 2 and 
principal component 3 scores in column 3. Since the plots on the diagonal are the 
principal components plotted against themselves the data is represented as a 
histogram to show the distribution of the scores within each principal component.  
In addition to the scatter plot matrices the clusters identified by k-means 
clustering are shown as different coloured points. For example, the scatter plots in Fig 
6a for PC3 v PC1 clearly indicate the presence of two distinct and non-overlapping 
clusters. Each of these clusters can be split into further non-overlapping clusters as 
indicated in Fig 6a as a result of k-means clustering in higher dimensions. By 
allowing the clusters to be visualised in the PCA score space, these scatter plots allow 
verification of the success of the k-means clustering for these datasets. By carrying 
out the principal component analysis first, the parameters which have less influence 
on the structures within the dataset have been removed thereby reducing noise and the 
dimensionality of the data.  
4.2.3. Parallel Co-ordinate Visualisation 
Next, the clustered data was converted back to values which have more meaning. This 
was done by separating the input dataset into the clusters identified by the k-means 
algorithm and this time plotting the original variables instead of the component scores 
on a series of ‘stacked’ parallel co-ordinate plots. This data is shown in Figure 7. 
Figure 7(a) shows the data from the base case 10,000L facility. Thirty parameters 
were input into the PCA algorithm however only the parameters of interest are shown 
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here. For clarity each parameter is normalised between -1 and 1 such that they can be 
easily compared. The result is a facility fingerprint. By comparing Figures 7(a) and 
(b) the wider impact of changing the tank volume can be quickly assessed.  
Each cluster of batches in Figure 7 has common characteristics that combined 
lead to different outcomes such as high mass losses. For example, an examination of 
cluster 4 in Figure 7(a) indicates that despite high titres, the cluster also exhibits high 
cost of goods. This can be attributed to a high average level of mass loss that was 
strongly linked to a high average eluate volume on the affinity step.  
Figures 7(a) and (b) can be compared together to understand how the facility 
fingerprint changes after the facility fix.  Before the fix (Figure 7(a)), all clusters of 
batches exhibit significant variance in product mass loss. After the fix (Figure 7(b)), 
the variance in mass loss can be seen to be removed as indicated by the pinch point 
formed across all clusters. Further comparison links this to the reduced variability in 
the number of chromatography cycles (affinity, AEX and CEX). This represents a 
significant improvement in the process schedule’s ability to absorb the uncertainty. 
The number of cycles overall may be higher in the modified facility, however they are 
more predictable which is often of greater importance.  
 
5. Conclusions 
This paper illustrates the insights that can be gained by integrating stochastic 
simulation data with advanced multivariate statistical techniques for predicting and 
understanding facility fit issues upon tech transfer. The Monte Carlo data enabled a 
greater degree of understanding of the impact of process fluctuations and subsequent 
facility fixes on the likelihood of meeting manufacturing targets. An early 
appreciation of risk allows for the planning of risk avoidance strategies such as 
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contingency batches or process changes. The effect of the facility fix identified was 
analysed in more detail with multivariate statistical analysis techniques that harnessed 
principal component analysis, clustering algorithms and high dimensional 
visualisation techniques combined to generate facility fingerprints. These allowed for 
rapid identification of process robustness and characteristics of clusters of batches that 
resulted in product losses and hence sub-optimal facility fit.  
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 Tables 
 
Table 1: Variable Distribution Ranges 
Variable Min Most Likely Max 
Product Titre -10% Base Case +10% 
Eluate Volumes -50% Base Case +50% 
Filter Flux Rates -10% Base Case +10% 
Step Yields    
Chromatography Steps 83% 95% 93% 
Virus Inactivation 98% 99% 100% 
Ultrafiltration/Diafiltration 90% 95% 99% 
Virus Retention Filtration 90% 95% 99% 
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Table 2: Facility Specification at 10,000L scale and expected 2g/L titre 
CHROMATOGRAPHY     
 Protein A AEX CEX 
Column diameter (m) 1 1 1 
Bed height (m) 0.20 0.25 0.15 
Bed volume (L) 157 196 118 
Load capacity (g/L) 25 50 15 
Linear velocity (cm/h) 450 450 140 
Expected number of cycles 6 2 8 
Expected pool* volume 
(CV/cycle) 
2 5.5 3 
Expected step yield (%) 88 88 88 
Virus inactivation volume 
(ml/L) 
58 N/A N/A 
    
FILTRATION    
 Post Protein 
A UF/DF 
Post AEX UF Final UFDF 
Retentate tank volume (L) 2500 2500 5000 
Expected ave. flux for 
UF/DF(L/m
2
h) 
100/55 110/60 140/80 
Target concentration (g/L) 25 25 38 
Diafiltration volumes 3 0 10 
Expected step yield (%) 99 99 99 
Note: Pool volume refers to the volume of the product stream. In Protein A and CEX 
steps operated in bind-and-elute mode this refers to the eluate volume collected. In 
AEX operated in flow-through mode this refers to the load volume plus a proportion 
of the post wash volume collected. 
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List of figures 
 
Figure 1: Base case process and facility. On the left the process sequence is shown 
along with estimated processing times. Note the process is split into three sections 
with each section aligned to a class of suite. The centre of the diagram shows the 
number and type of processing suites within the facility. The circles represent the 
different suites with the arrows showing the route process material can take.  CC = 
cell culture, Cent = centrifugation, ProA = Protein A, VI = virus inactivation, UFDF = 
Ultrafiltration/Diafiltration, AEX = anion exchange, CEX = cation exchange, VRF = 
virus retention filtration, DSP = downstream processing, VS  = virus secure. 
 
Figure 2: Probability distributions for the throughput predicted from both the base 
case (-----) and modified (- - -) 10,000L facility. Fluctuations assumed for cell culture 
titre (2g/L ± 0.2; harvest kg/batch = 20 ± 2), step yields, eluate volumes, filtration flux 
rates. (n=1000) 
 
Figure 3: Distribution of pool volumes for each step given expected fluctuations in the 
(a) base case and (b) modified 10,000L facility data. Vertical bars are composed of a 
series of horizontal dashes, each representing the pool volume from a single 
simulation iteration. For clarity the distribution of values is shown by the histogram 
alongside each bar.  Fluctuations assumed for cell culture titre (2g/L ± 0.2; harvest 
kg/batch = 20 ± 2), step yields, eluate volumes, filtration flux rates. Note: Pool 
volume refers to the volume of the product stream. In Protein A and CEX steps 
operated in bind-and-elute mode this refers to the eluate volume collected. In AEX 
operated in flow-through mode this refers to the load volume plus a proportion of the 
post wash volume collected. (n=1000). 
 
Figure 4: Probability plot showing the probability of meeting a range of demands 
within three batches using either the base case (-----) and modified (- - -) 10,000L 
facility. Fluctuations assumed for cell culture titre (2g/L ± 0.2; harvest kg/batch = 20 
± 2), step yields, eluate volumes, filtration flux rates. (n=1000) 
 
Figure 5: Scree plots generated from the principal component analysis of the (a) base 
case and (b) modified 10,000L facility data. 
 
Figure 6. Clustered scatter matrices showing the score values for the first three 
principal components generated by the PCA of the (a) base case and (b) modified 
10,000L facility data. k-means clustering was used on the first 5 principal 
components, 3 are shown for clarity. Along the diagonal, histograms are shown of the 
distributions of scores within each principal component, (n=1000) 
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Figure 7: Vertical parallel co-ordinate plot showing PCA clustered data for the (a) 
base case and (b) modified 10,000L facility data. Fluctuations assumed for cell 
culture titre (2g/L ± 0.2; harvest kg/batch = 20 ± 2), step yields, eluate volumes, 
filtration flux rates. Note: for AEX operated in flow-through mode, the AEX eluate 
vol refers to the load volume plus a proportion of the post wash volume collected. 
(n=1000) 
 
Figure A.1: An example dendrogram generated from the outputs from principal 
component analysis of the base case 10,000L facility data used to identify 6 distinct 
clusters (seen where distance between clusters = 20 units). 
. 
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Figure 1: Base case process and facility. On the left the process sequence is shown 
along with estimated processing times. Note the process is split into three sections 
with each section aligned to a class of suite. The centre of the diagram shows the 
number and type of processing suites within the facility. The circles represent the 
different suites with the arrows showing the route process material can take.  CC = 
cell culture, Cent = centrifugation, ProA = Protein A, VI = virus inactivation, UFDF = 
Ultrafiltration/Diafiltration, AEX = anion exchange, CEX = cation exchange, VRF = 
virus retention filtration, DSP = downstream processing, VS  = virus secure.  
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Figure 2: Probability distributions for the throughput 
predicted from both the base case (-----) and modified (- - -) 
10,000L facility. Fluctuations assumed for cell culture titre 
(2g/L ± 0.2; harvest kg/batch = 20 ± 2), step yields, eluate 
volumes, filtration flux rates. (n=1000) 
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(a) 
 
(b) 
 
Figure 3: Distribution of pool volumes for each step given 
expected fluctuations in the (a) base case and (b) modified 
10,000L facility data. Vertical bars are composed of a series 
of horizontal dashes, each representing the pool volume from 
a single simulation iteration. For clarity the distribution of 
values is shown by the histogram alongside each bar.  
Fluctuations assumed for cell culture titre (2g/L ± 0.2; 
harvest kg/batch = 20 ± 2), step yields, eluate volumes, 
filtration flux rates.  Note: Pool volume refers to the volume 
of the product stream. In Protein A and CEX steps operated 
in bind-and-elute mode this refers to the eluate volume 
collected. In AEX operated in flow-through mode this refers 
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 to the load volume plus a proportion of the post wash volume 
collected. (n=1000).  
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Figure 4: Probability plot showing the probability of meeting 
a range of demands within three batches using either the base 
case (-----) and modified (- - -) 10,000L facility. Fluctuations 
assumed for cell culture titre (2g/L ± 0.2; harvest kg/batch = 
20 ± 2), step yields, eluate volumes, filtration flux rates. 
(n=1000) 
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Figure 5: Scree plots generated from the principal component 
analysis of the (a) base case and (b) modified 10,000L facility 
data. 
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Figure 6. Clustered scatter matrices showing the score values for the first three 
principal components generated by the PCA of the (a) base case and (b) modified 
10,000L facility data. k-means clustering was used on the first 5 principal 
components, 3 are shown for clarity. Along the diagonal, histograms are shown of the 
distributions of scores within each principal component, (n=1000) 
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Figure 7: Vertical parallel co-ordinate plot showing PCA clustered data for the (a) 
base case and (b) modified 10,000L facility data. Fluctuations assumed for cell 
culture titre (2g/L ± 0.2; harvest kg/batch = 20 ± 2), step yields, eluate volumes, 
filtration flux rates. Note: for AEX operated in flow-through mode, the AEX eluate 
vol refers to the load volume plus a proportion of the post wash volume collected. 
(n=1000) 
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Appendix 1 
 
 
 
Figure A.1: An example dendrogram generated from the outputs from principal 
component analysis of the base case 10,000L facility data used to identify 6 distinct 
clusters (seen where distance between clusters = 20 units). 
Distance between clusters 
